ABSCIENCES (EPA:AB) AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease
Transparency directive : regulatory news
21/11/2022 18:09